Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | QPCT | Q16769 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1190927 | 0.78 | — | — | |
| SCHEMBL1191057 | 0.75 | PRKAG1 (0.48) | ALDH1A1KDM4ESMN1; SMN2HPGD | |
| SCHEMBL5788988 | 0.75 | ALDH1A1 (0.56) | HTTALDH1A1KDM4ESMN1; SMN2HPGD | |
| SCHEMBL1191219 | 0.74 | — | — | |
| SCHEMBL4476710 | 0.74 | ALDH1A1 (0.46) | ALDH1A1KDM4ESMN1; SMN2HPGDRXFP1 | |
| SCHEMBL1190425 | 0.72 | ALDH1A1 (0.57) | ALDH1A1KDM4ESMN1; SMN2HPGD | |
| SCHEMBL2329966 | 0.72 | HTT (1.00) | HTTALDH1A1KDM4EL3MBTL1RXFP1 | |
| SCHEMBL1040106 | 0.71 | — | — | |
| SCHEMBL2902729 | 0.71 | MAPT (0.55) | HTTALDH1A1KDM4ESMN1; SMN2HPGD | |
| SCHEMBL2897388 | 0.71 | PRKAB2 (0.47) | HTTALDH1A1KDM4ESMN1; SMN2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8193215-B2 | Thieno[2 3-b]pyridines as potassium channel inhibitors | XENTION LIMITED (GB) | 2012-06-05 | — | — | US | disclosed |
| EP-1879899-B1 | THIENOPYRIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS | XENTION LTD (GB) | 2010-08-04 | — | — | EP | disclosed |
| US-20100041695-A1 | Thieno[2,3-b]pyridines as Potassium Channel Inhibitors | XENTION LIMITED (GB) | 2010-02-18 | — | — | US | disclosed |
| US-7576212-B2 | Thieno[2,3-B] pyridines as potassium channel inhibitors | XENTION LIMITED (GB) | 2009-08-18 | — | — | US | disclosed |
| EP-1879899-A1 | THIENOPYRIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS | Xention Discovery Limited (GB) | 2008-01-23 | — | — | EP | disclosed |
| US-20060183768-A1 | Compounds | XENTION DISCOVERY LTD. (GB) | 2006-08-17 | — | — | US | disclosed |
| WO-2006061642-A1 | COMPOUNDS | XENTION DISCOVERY LIMITED (GB) | 2006-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041695-A1 | Thieno[2,3-b]pyridines as Potassium Channel Inhibitors | SCN8A, SCN1B, SCN2B | HTT 3498/4885ALDH1A1 3155/4885KDM4E 2290/4885 |
| US-20060183768-A1 | Compounds | SCN7A, CBR3, SCN8A | HTT 2632/4885ALDH1A1 2799/4885KDM4E 3169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.